Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

Stock Information for GlucoTrack Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GlucoTrack Inc.

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and L?kahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing
Glucotrack, Inc. and L?kahi Therapeutics(TM) Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
UPDATE - Glucotrack and L?kahi Therapeutics Complete Strategic Business Combination, Establishing L?kahi-Controlled Public Platform
Glucotrack and L?kahi Therapeutics Complete Strategic Business Combination, Establishing L?kahi-Controlled Public Platform
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.